Bio-IT World July 15, 2022
Contributed Commentary by Per Hammer, Cytiva

Historically, the heavily regulated biopharma industry has been slow to adopt new technologies. However, a shift toward automation is vital to ensure that next-generation solutions–such as cell and gene therapies–are produced at scale.  

Less than one in five senior pharma executives strongly believe that frontier technologies, such as artificial intelligence, are widely adopted to support automation and increase the speed of specific processes. With cell therapies approved by global regulatory bodies, it is time to accelerate smart technologies and cell and gene therapy manufacturing.  

Today’s cell therapy treatments are often made on a small-scale, include manual preparation steps, and are produced for a clinical trial setting. Researchers spend days processing cellular material, monitoring its growth...

Today's Sponsors

Oliver Wyman
Upfront Healthcare

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Pharma / Biotech, Precision Medicine
Executive Interviews at Fierce Biotech Summit 2022
New AI precision medicine tool adopted by UCLA, Rush, other health systems
The American Heart Association Launches Precision Medicine Platform, New Proprietary Computational Models for Oncology Drug Discovery, More
Examining mRNA vaccine effectiveness for immunocompromised adults during omicron BA.4 and BA.5 predominance
Biotech's newest odd couple: A pharma insider and a music maven launch a health care VC